Cystine Inhibitors
1 drugsAbout Cystine
Cystine is a dimer of cysteine linked by a disulfide bond, crucial for protein structure, redox regulation, and cellular metabolism. Disruptions in cystine metabolism can lead to various health issues.
Cystine is a therapeutic target due to its involvement in key cellular processes; however, there is currently no genetic evidence linking it to specific diseases.
Cystine is currently targeted by one FDA-approved drug, CYSTAGON, a small molecule approved in 1994 and marketed by Viatris for one indication.
Top Cystine Drugs
The competitive landscape is limited, with only one company, Viatris, having an approved drug targeting Cystine.
Low competition suggests an opportunity for new entrants, but also indicates potential challenges in market viability.
Cystine Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Cystine, using small molecule modality.
Exploring alternative modalities like antibodies or gene therapies could offer a competitive advantage.
Cystine Clinical Trials 14 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Cystine. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 5 | 5 | 0 | 0 | 100% |
| Phase 2 | 5 | 4 | 1 | 0 | 80% |
| Phase 3 | 4 | 3 | 0 | 1 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Cystine Drug Approval Timeline (1994 - 1994)
The first and only drug targeting Cystine, CYSTAGON, was approved in 1994.
The lack of recent approvals suggests a saturated market or challenges in developing new Cystine-targeting therapies.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 9 (3 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Cystine. A trial counts if an approved drug acting on Cystine is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.